FAM
MACK

Fred Alger Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Fred Alger Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,811
Closed -$610K – 630
2015
Q4 		$610K Buy
+9,811
New +$690K ﹤0.01% 423
2013
Q3 		– Sell
-99,483
Closed -$5.28M – 611
2013
Q2 		$5.28M Buy
+99,483
New +$4.36M 0.03% 342

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Fred Alger Management's MACK Position: Q1 2016 in Review

Fred Alger Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 9,811 shares — an estimated $610K sold.

Fred Alger Management first reported a position in MACK in Q2 2013 and held it in 2 quarters. The position peaked at $5.28M in Q2 2013. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

  • Fred Alger Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Fred Alger Management sold 9,811 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $610K.
  • Fred Alger Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Fred Alger Management's Merrimack Pharmaceuticals, Inc. position peaked at $5.28M in Q2 2013.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on Fred Alger Management's 13F filing for Q1 2016, filed 16 May 2016.